Aquestive(AQST)
搜索文档
Aquestive(AQST) - 2024 Q1 - Quarterly Results
2024-05-08 04:21
Exhibit 99.1 Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen and other injectors used for the treatment of anaphylaxis • On track to complete Anaphylm temperature/pH study in second quarter 2024 • Received positive feedback from FDA on Anaphylm self-administration and allergen exposure protocols; remains on track to complete b ...
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Newsfilter· 2024-05-08 04:19
Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen® and other injectors used for the treatment of anaphylaxisOn track to complete Anaphylm temperature/pH study in second quarter 2024Received positive feedback from FDA on Anaphylm self-administration and allergen exposure protocols; remains on track to complete both studies in third quarter 2024Continues to target filing an Anaphylm New Drug Application (NDA) with the FDA by th ...
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Newsfilter· 2024-04-29 19:00
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of ageCompany track record now includes 4 FDA approvals since 2018Anaphylm program on track; NDA submission expected by the end of 2024Hosts conference call for investors on April 29 at 8:00 a.m. ET WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Aquestiv ...
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
Newsfilter· 2024-04-13 04:01
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company's product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual M ...
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
GlobeNewsWire· 2024-04-13 04:01
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual ...
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Seeking Alpha· 2024-04-09 13:25
公司背景 - Aquestive Therapeutics是一家专注于利用专有PharmFilm平台开发和商业化差异化产品的制药公司[3] - 公司已经建立了一个强大的产品组合,拥有五个FDA批准的产品和八个成功的合作伙伴关系,以及拥有超过150项全球专利[5] 产品管线和重点项目 - 公司的产品管线主要关注中枢神经系统疾病和过敏性休克,旨在满足未满足需求或推动标准护理的产品和候选药物[6] - 公司正专注于Adrenaverse前药平台,其中包含超过20种能够调节吸收和转化速率的肾上腺素前药,可适用于各种剂量方法和给药位置[7] - Anaphylm的第三阶段关键药代动力学/药效学研究成功达到主要和次要终点,提供了快速和持续的肾上腺素水平,为当前护理标准提供了无针替代品[9] 财务状况和展望 - 在2023年,Aquestive经历了实质性的收入增长,全年总收入从2022年的4000万美元增长至2023年的5060万美元,增长了26%。2023年,Aquestive的净亏损为790万美元,较2022年的5440万美元有所下降。截至2023年,Aquestive的现金为2390万美元。2024年,Aquestive的收入预期在4800万美元至5100万美元之间[8] - 街头的收入预测显示,他们认为Aquestive将在下一个十年经历强劲的双位数收入增长,并将接近将近50亿美元的收入,这将低于1倍的前瞻性销售价格[17] - 考虑到行业的平均价格销售额约为4-5倍,我们可以说Analphylm的批准应该改善AQST在2020年余下时间的前景[18] 风险和挑战 - Aquestive Therapeutics将不得不应对许多小市值医疗保健公司必须面对的固有风险。主要是,Analphylm尚未通过FDA的最终审核,每一步前进都带来挫折和失败的风险。一次失败的FDA检查或数据不准确可能会使公司和股价陷入长时间的困境[19] - 即使公司成功将Anaphylm通过FDA,公司也必须担心市场主导的自动注射器的内在竞争。尽管Anaphylm有可能成为市场颠覆者,但要立即摆脱内在竞争将是困难的。因此,Anaphylm有可能未能达到亿美元级别的销售额,并将走上一条漫长的道路,达不到高峰销售额[20] - 公司在2023年以2390万美元的现金结算,刚刚从公开发行中筹集了大约7500万美元,因此他们应该有足够的资金度过今年。然而,商业化成本以及资助他们的管线和维持运营可能会导致现金头寸在短时间内消失。不幸的是,很难预测这笔现金的持续时间。因此,投资者需要接受公司可能在未来几个季度再次进行发行,以筹集资金来资助潜在的上市,如果他们无法找到商业合作伙伴[21]
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
Zacks Investment Research· 2024-04-03 07:21
公司股价表现 - Aquestive Therapeutics (AQST) 最近的股价为 $4.14,较前一交易日收盘价上涨了 +0.24% [1] - 公司股价在过去一个月中下跌了 1.2%,落后于医疗行业的下跌幅度为 0.03% 和标普500指数的上涨幅度为 2.16% [2] 财务预期 - 投资者将密切关注 Aquestive Therapeutics 即将发布的财报。预计公司将报告每股收益为 -$0.08,较去年同期下降了 172.73%;同时,最新的共识预期公司营收为 $12.55 百万美元,较去年同期增长了 12.76% [3] - 根据 Zacks Consensus Estimates,全年预计公司每股亏损为 -$0.36,营收为 $50.64 百万美元,较去年分别下降了 176.92% 和增长了 0.1% [4] 分析师预期和评级 - 分析师对 Aquestive Therapeutics 的最新预期调整也值得投资者注意。这些调整通常反映了最新的短期业务趋势,可以频繁变化。因此,预期的积极调整传达了分析师对公司业绩和利润潜力的信心 [5] - Zacks Rank 系统从 1 (强热门) 到 5 (强卖出),经第三方审计验证,自 1988 年以来,排名为 1 的股票平均年回报率为 +25%。过去一个月,Zacks Consensus EPS 预期下降了 6.93%。Aquestive Therapeutics 目前持有 Zacks Rank 3 (持有) [7] 行业评级 - 医疗-药品行业属于医疗行业。该行业目前的 Zacks Industry Rank 为 91,在所有 250+ 个行业中处于前 37% [8] - Zacks Industry Rank 通过计算各个行业组内个别股票的平均 Zacks Rank 来评估我们各个独立行业组的实力。研究显示,排名前 50% 的行业的表现比排名后 50% 的行业好一倍 [9]
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
Zacks Investment Research· 2024-03-23 07:06
公司表现 - Aquestive Therapeutics (AQST) 最近的股价为$4.38,与前一个交易日相比没有变化[1] - 过去一个月,这家专业制药公司的股价上涨了66.54%,领先医疗行业的0.88%增长和标普500指数的5.34%增长[2] 财务预测 - 投资者将密切关注Aquestive Therapeutics在即将公布的财报中的表现。预计公司将发布每股收益为-$0.09,较去年同期下降了181.82%。同时,Zacks对营收的预测为1247万美元,比去年同期增长了12%[3] - AQST全年的Zacks共识预测为每股亏损$0.38,营收为5085万美元。这些结果将分别较去年同期变化为-192.31%和+0.52%[4] 分析师预测 - 最近分析师对Aquestive Therapeutics的预测也应引起投资者的注意。这些最近的修订往往反映了短期业务趋势的变化。因此,预测上调表明分析师对公司的业务运营和盈利能力持乐观态度[5] - 研究表明,这些预测变化与未来股价表现直接相关。为了从中受益,公司开发了Zacks Rank,这是一个专有模型,考虑了这些预测变化并提供可操作的评级系统[6] 行业排名 - 医疗-药品行业属于医疗行业。该行业目前的Zacks行业排名为145,在所有250+个行业中处于倒数43%的位置[8] - Zacks行业排名通过测量组内个别股票的平均Zacks Rank来衡量我们行业群体的实力。我们的研究显示,排名前50%的行业的表现比后50%的行业好一倍[9]
Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today?
InvestorPlace· 2024-03-20 20:46
Aquestive Therapeutics(NASDAQ:AQST)公开发行股票 - 每股售价为$4.50[1] - 预计募集到7500万美元的总收益,用于产品管线的开发和商业化[2] - 公开发行增加了AQST股票的总流通股数,导致股东持股比例被稀释[4]
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
Newsfilter· 2024-03-20 09:49
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting disc ...